Three cases of endometrial cancer associated with "bioidentical" hormone replacement therapy.

University of New South Wales, Sydney, NSW, Australia.
The Medical journal of Australia (Impact Factor: 3.79). 09/2007; 187(4):244-5.
Source: PubMed

ABSTRACT We describe three women who developed endometrial cancer after taking "bioidentical" hormone replacement therapy (HRT) to relieve menopausal symptoms. Although pharmaceutical HRT is a well established and tested therapy, little is known about the quality control, safety and efficacy of bioidentical HRT. Women should be advised to avoid bioidentical HRT, and those who continue to use it should receive regular endometrial surveillance.

  • [Show abstract] [Hide abstract]
    ABSTRACT: For many years, hormone therapy (HT), administered as estrogen alone (for hysterectomized women) or combined estrogen/progestin (for nonhysterectomized women), has been an effective treatment for menopausal symptoms and osteoporosis prevention. Questions regarding the benefit–risk profile of HT have prompted some women to seek alternative therapies. Compounded bioidentical HT has been promoted as a potentially safer option than conventional HT; however, there are a lack of sufficient data from well-designed comparative trials to support the safety or efficacy of this approach. Compounded bioidentical hormone formulations may be associated with additional risks for variability in quality, purity, and batch-to-batch consistency.
    The Journal for Nurse Practitioners 06/2009; 5(6):421-427. DOI:10.1016/j.nurpra.2009.03.011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract After the publication of the Women's Health Initiative, attitudes towards management of menopausal symptoms changed dramatically. One alternative that has received much media attention is the use of bioidentical hormone therapy (BHT). The media and celebrity endorsements have promoted a number of misconceptions about the risks and benefits associated with the various forms of BHT. This article will review the available evidence regarding the safety and efficacy of BHT in comparison to conventional hormone therapy. We will also review several cases seen in our midlife women's referral clinics, which demonstrate concerns for the safety and efficacy of BHT, including unexplained endometrial cancer in otherwise healthy BHT users. Due to the lack of sufficient data to support the efficacy or safety of BHT, we recommend the use of United States Food and Drug Administration-approved regimens in the management of menopausal symptoms.
    Journal of Women's Health 08/2014; 23(8):642-648. DOI:10.1089/jwh.2014.4770 · 1.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Menopausal symptoms affect a significant portion of women. Traditional treatment with manufactured hormone therapy can alleviate these symptoms, but many women and their health care providers are concerned about the risks, such as venous thromboembolism and certain types of cancer, demonstrated with manufactured hormone therapy. Compounded bioidentical hormone therapy has been proposed and is often used as a solution for these concerns. Despite this use, no data are currently available to support the claims that compounded bioidentical hormone therapy is a safer or more efficacious option compared with manufactured hormone therapy. A common misperception is that all manufactured products consist of synthetic hormones and all compounded medications consist of natural hormones; however, in fact, significant overlap exists. Several key stakeholder organizations have issued statements expressing concern about the lack of evidence regarding the efficacy and safety of compounded bioidentical hormone therapy, in addition to concerns regarding prescribing patterns. The Women's Health Practice and Research Network of the American College of Clinical Pharmacy recommends against the consistent use of compounded bioidentical hormones as a safer option compared with manufactured therapy and supports the statements of other key organizations, acknowledging the need for more robust clinical studies to evaluate the potential advantages and disadvantages of compounded bioidentical products compared with manufactured products.
    Pharmacotherapy 01/2014; DOI:10.1002/phar.1394 · 2.31 Impact Factor


Available from